{"id":"standard-treatment-with-benznidazole","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Benznidazole is a nitroimidazole derivative that is activated by the parasite's cellular enzymes, leading to the formation of reactive intermediates that damage the parasite's DNA and inhibit its growth. This results in the death of the parasite and the resolution of the infection.","oneSentence":"Benznidazole is an antiparasitic drug that works by inhibiting the growth of the parasite Trypanosoma cruzi.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:26.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chagas disease"}]},"trialDetails":[{"nctId":"NCT03672487","phase":"PHASE3","title":"Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tulane University School of Public Health and Tropical Medicine","startDate":"2019-06-01","conditions":"Chagas Disease","enrollment":273},{"nctId":"NCT06339710","phase":"PHASE3","title":"Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients","status":"WITHDRAWN","sponsor":"Evandro Chagas Institute of Clinical Research","startDate":"2025-01-30","conditions":"Chronic Chagas Disease","enrollment":""},{"nctId":"NCT04897516","phase":"PHASE3","title":"Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease","status":"RECRUITING","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2021-07-28","conditions":"Chagas Disease","enrollment":300},{"nctId":"NCT01162967","phase":"PHASE2","title":"Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2010-09","conditions":"Chagas Disease","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":122,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Benznidazole 8 weeks"],"phase":"phase_3","status":"active","brandName":"Standard treatment with benznidazole","genericName":"Standard treatment with benznidazole","companyName":"Laboratorio Elea Phoenix S.A.","companyId":"laboratorio-elea-phoenix-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benznidazole is an antiparasitic drug that works by inhibiting the growth of the parasite Trypanosoma cruzi. Used for Chagas disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}